This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Will be an interesting week I feel.

cheers GF.

A positive opening.

cheers GF.

What is mind-blowing is waiting for this news, we've been waiting since September, I thought MMG said they had intentions to keep holders more informed!! Doesn't look like it and thats why sp is so crap for their portfolio and potential. Come on MMG, sell yourself better before people get bored.
I'm sure the institutions who keep lending out the loot want more progress before they spend again!!

Stay cool andy, its coming.

cheers GF.

MMG have been coming for ages, maybe they are developing a pill to last longer!!
Now that would have a good market!!! I'm still holding!!

Up 10% on the day and news to come soon...take my brokers word for it.Whatever you do dont get too impatient as the news will be good.

Blimey fella's. 10 p/cent. that is a nice welcome home tonight, hang in there.


Anybody hold Anglo Pacific???????????? have just hit 100 p/cent gain sell signal for me, I know you should keep to your strategy but this still looks like its going strong..... any comments welcome


Cheers. Rob

THIS IS JUST THE START GUYS, excelent news.

Medical Marketing Int'l Group PLC
28 January 2005


For Immediate Release 28 January 2005


MMI's ruthenium cancer therapy passes independently verified safety tests


Medical Marketing International Group plc (AIM:MMG), the Cambridge, UK-based
pharmaceutical development company today announces that lead ruthenium compounds
within its portfolio of cancer therapies show toxicity at an even safer level
than the safest cancer drug currently available, when tested in an industry
standard laboratory model.

Independent laboratory tests show ruthenium to have a low toxicity profile

Efficacy of ruthenium shown to be better than market-leading platinum drugs

Patents recently granted in biggest markets, USA and EU giving long patent
protection. Other patents are pending.


MMI has already shown that the ruthenium cancer therapies within its
wholly-owned subsidiary, Oncosense, appear in laboratory tests to be more
powerful than the platinum-based drugs which have been some of the most
successful cancer drugs for decades and which had peak sales of $5bn. Efficacy
of these compounds has also been independently demonstrated in both human cancer
cells and in vivo models. MMI recently announced that patents in USA and Europe,
the two biggest markets have been granted, and other patents are pending.

MMI used the Dundee-based specialist, CXR Biosciences Ltd to test the most
promising ruthenium compounds for potential toxicity. A summary of the CXR
results is announced today.


Mark Burton, Technical Manager at MMI said: 'We chose CXR because of their
highly regarded expertise in screening new drugs for harmful effects. Not only
did CXR deliver the results on time and on budget, they were able to show that
our ruthenium cancer therapies demonstrate a low toxicity profile. These
results, when added to the existing efficacy data show that ruthenium has great
clinical potential.'


Dr Cliff Elcombe Director at CXR and former Senior Scientist at Zeneca said: 'We
feel privileged to have been chosen by MMI to carry out the safety studies on
what now appears to be an extremely interesting new class of cancer drugs. The
safety screens that we performed indicate that this new group of cancer
therapies has enormous potential.'


Executive Chairman of MMI Group, David Best, commenting on these results said: '
Ruthenium is only one of MMI's portfolio of excellent drug candidates, but
already data show it to be potentially the most effective drug against serious
cancers like lung, colon and ovarian. This new data from CXR shows ruthenium to
be potentially relatively safe too. If these results are confirmed in the
clinical trials, then ruthenium may improve significantly on the standard
treatment for cancer patients and become a major commercial success in a cancer
therapy market that was worth $42 billion in 2004 and continues to grow in
double-digit figures.'


For further information, please contact:

David Best - Executive Chairman

cheers GF.

Added more MMG this one could be the share of the year, and blast away.

cheers GF.

Killicks name it as a company with potentially significant upside....! no sp predictions but I reckon they are advising their clients to buy up to 200p(my guess)..cheers.

Here it is Mitzy. From Killik Brokers...................

MEDICAL MARKETING Ruthenium update



We highlighted Medical Marketing last year as a potentially interesting proposition and this morning, a pipeline update announcement confirms the potential. The company has an investment in the project that is investigating the base metal of ruthenium as an alternative to platinum. In a surprising development, the company announces that under tests, the lead compounds have shown toxicity levels at an even safer level than the safest cancer drug on the market at the moment. The news is extremely encouraging and will expand the potential market for its offering by allowing it to be used as a treatment at an early stage.



The company will review which of its lead compounds will be taken to trial and this conversation will take place with the regulator. The timeframe for this is still somewhat up in the air but certainly further news flow can be anticipated in the next few months. We further expect more news flow from the group in the on other areas including results from the Genvax vaccine trial.



The company still has a modest market capitalization of around 40 million but given its pipeline, offers potential significant upside. The sector is high risk although money has been moving back following recent mergers (Oxford Biomedica for one) and one suspects this could be an exciting sector to watch for 2005. Medical Marketing remains our preferred choice in this space.



cheers GF.

Thats the one..! cheers gf.

Still holding since last March and glad it continues to look promising. Nice to see my holding back in the blue. This news now gives me the confidence to add on any dips which seem to happen when there is no news from MMG. Maybe when/if this happens again I may not be so p'd off but look as opportunity.

Should get plenty of financial press coverage andy during the next week or so and cant help but be very bullish on this one.

cheers GF.

Buyers coming in at the death, quick get in before they move further up.

cheers GF.

wow at last.... I promise never to bleat again my portfolio being overweight with mmg. well done for hanging in guys. cheers....Rob

Price target as to be off the screen, just dont think how many have caught onto this one yet. Never mind freed some dosh up this weekend and will have another tranche.

cheers GF.

From Uk analyst this weekend,...................

A positive drug update from Medical Marketing International on its ruthenium cancer therapy caused the shares to jump 9p to 81p. It said the product had passed independently-verified safety tests, showing toxicity at an even safer level than the safest cancer drug currently available, when tested in an industry standard laboratory model. The company said that if these results are confirmed in the clinical trials, then ruthenium may improve significantly on the standard treatment for cancer patients and become a major commercial success in a cancer therapy market. The group noted that this was worth 42 billion dollars in 2004 and continued to grow in double-digit figures.

cheers GF.

Any price targets GF..?

.